Outcome of Patients supported with HeartMate 3 after Extra-corporeal Life Support. On behalf of Durable MCS after ECLS Study Group

Objectives Durable mechanical circulatory support system (MCS) after (extra-corporeal Life Support (ECLS) registry is a multicenter registry of patients who were bridged from ECLS to durable MCS. While numerous studies have highlighted the favorable outcomes following HeartMate 3 (HM3) implantation, the objective of our study is to examine the outcomes of patients who received HeartMate 3 support after ECLS. Methods Data of patients undergoing HM 3 implantation from 01.2016 thru 04.2022 at 14 centers are collected and evaluated. Inclusion criteria were patients with ECLS support prior to HM3 implantation. The outcome was reported and compared to patients receiving other types of pumps. Results A total of 337 patients were bridged to durable MCS after ECLS in the study period. Out of those patients, 140 patients were supported with HM3. The other types of pumps included 170 HeartWare HVAD (86%), 14 HeartMate II (7%) and 13 (7%) other pumps (7%). Major postoperative complications included right heart failure requiring temporary right VAD in 60 patients (47%). A significantly lower postoperative stroke (16% vs. 28%, p= 0.01) and pump thrombosis (3% vs. 8 %, p= 0.02) rates were observed in the HM 3 patients. The 30 day, 1 year and 3 year survival in HM3 patients was 87%, 73% and 65% respectively. Conclusions In this critically ill patient population, the survival rates of patients who were transitioned to HeartMate 3 are deemed acceptable and superior to those observed when ECLS was bridged to other types of durable MCS.